Certara Announces New Leadership Appointment
Certara, Inc. (NASDAQ: CERT) has announced that Adrian McKemey, Ph.D., is stepping into the role of President of Drug Development Solutions. This strategic move marks an essential step in Certara's evolution, enhancing their leadership in model-informed drug development.
Adrian McKemey's Background
Dr. McKemey joins Certara with a rich background in the pharmaceutical industry, most recently serving as the head of Enterprise Transformation at IQVIA and as Senior Vice President at Quintiles, where he led R&D strategy solutions. His impressive experience spans over 25 years, focusing on R&D strategies, business transformation, and portfolio management.
Leadership Transition
The appointment of Dr. McKemey is part of a planned transition within Certara's leadership. Patrick Smith, PharmD., will continue to play a crucial role within the company as the Senior Vice President of Translational Sciences, where he will support Certara’s ongoing growth in innovation and scientific advancements.
Enhancing Drug Development
William Feehery, Ph.D., CEO of Certara, expressed optimism regarding the new appointment, stating that Dr. McKemey's mission-driven approach is vital for advancing drug development. His leadership will further boost the capabilities of Certara’s biosimulation and scientific services, targeting the development of the next generation of transformative therapies.
Certara’s Vision for the Future
Dr. McKemey highlighted the importance of biosimulation in today’s clinical development landscape. He emphasized that the integration of in silico models can significantly improve success rates in clinical trials at both the asset level and overall portfolio. He sees his new role as a unique opportunity to positively impact the pharmaceutical industry and expedite the delivery of vital medications to patients.
About Certara
Certara is at the forefront of transforming traditional drug discovery methods. Utilizing advanced biosimulation software and technology, the company serves over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Discover more about their innovative solutions at certara.com.
Certara Contact Information
For inquiries, please contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Relations Contact
Alyssa Horowitz
certara@pancomm.com
Frequently Asked Questions
Who is the new president of Drug Development Solutions at Certara?
Dr. Adrian McKemey has been appointed as the new president of Drug Development Solutions at Certara.
What is Dr. McKemey’s experience in the pharmaceutical industry?
He has over 25 years of experience, previously serving in leadership roles at IQVIA and Quintiles, focusing on R&D strategies and business transformation.
What role will Patrick Smith continue to have at Certara?
Patrick Smith will stay on as Senior Vice President of Translational Sciences, supporting the company’s growth in innovation.
How does Certara enhance drug development?
Certara uses biosimulation software and services to improve drug discovery and development processes for their clients globally.
How can I contact Certara for more information?
You can reach out to Sheila Rocchio at sheila.rocchio@certara.com for inquiries.